Kim Cocks
Overview
Explore the profile of Kim Cocks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
1992
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hummel H, Ahn M, Blackhall F, Reck M, Akamatsu H, Ramalingam S, et al.
Adv Ther
. 2025 Mar;
PMID: 40025391
Introduction: Tarlatamab demonstrated a durable response and promising survival outcomes in patients with previously treated small cell lung cancer (SCLC) in the phase 2, open-label DeLLphi-301 trial. Patient-reported outcomes (PROs)...
2.
Clarke N, Worthy G, Payakachat N, Gilligan A, Cocks K
Qual Life Res
. 2025 Jan;
PMID: 39847268
Purpose: Meaningful change thresholds are important to help interpret patient-reported outcome scores. To date, meaningful within-patient change (MWPC) thresholds have only been proposed for NSCLC-SAQ total score. This study proposed...
3.
Cocks K, King-Kallimanis B, Sims J, Worthy G, Stein J, Ayala-Nunes L, et al.
J Patient Rep Outcomes
. 2024 Dec;
8(1):150.
PMID: 39694990
Background: Time to deterioration (TTD) endpoints are often utilized in the analysis of patient-reported outcome (PRO) data in oncology clinical trials but different endpoint definitions and analysis frameworks exist that...
4.
Clarke N, Braverman J, Worthy G, Shaw J, Bennett B, Dhanda D, et al.
Value Health
. 2024 Jan;
27(4):458-468.
PMID: 38191023
Objectives: This literature review provides an overview of meaningful change thresholds for the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) and the...
5.
Holch P, Turner G, Keetharuth A, Gibbons E, Cocks K, Absolom K
J Patient Rep Outcomes
. 2023 Nov;
7(1):121.
PMID: 38010558
Background: PROs are valuable tools in clinical care to capture patients' perspectives of their health, symptoms and quality of life. However the COVID-19 pandemic has had profound impacts on all...
6.
Oerlemans S, Efficace F, Shamieh O, Borges F, de Jong C, Dong D, et al.
Blood Adv
. 2023 Sep;
7(22):7045-7055.
PMID: 37738090
Hodgkin lymphoma (HL) has become 1 of the most curable cancers. Therefore, rigorous assessment of health-related quality of life (HRQoL) and symptom burden of these patients is essential to support...
7.
King-Kallimanis B, Calvert M, Cella D, Cocks K, Coens C, Fairclough D, et al.
Value Health
. 2023 Jul;
26(10):1543-1548.
PMID: 37422075
Objectives: Patient-reported outcome (PRO) data are critical in understanding treatments from the patient perspective in cancer clinical trials. The potential benefits and methodological approaches to the collection of PRO data...
8.
Musoro J, Coens C, Sprangers M, Brandberg Y, Groenvold M, Flechtner H, et al.
Eur J Cancer
. 2023 May;
188:171-182.
PMID: 37257278
Introduction: Early guidelines for minimally important differences (MIDs) for the EORTC QLQ-C30 proposed ≥10 points change as clinically meaningful for all scales. Increasing evidence that MIDs can vary by scale,...
9.
Oerlemans S, Efficace F, Kyriakou C, Freitas A, Shamieh O, Creutzberg C, et al.
Cancer
. 2023 May;
129(17):2727-2740.
PMID: 37204189
Background: Health-related quality of life (HRQOL) is a critical aspect to consider when making treatment decisions for patients with non-Hodgkin-lymphoma (NHL). This international study by the European Organisation for Research...
10.
Hirji I, Cocks K, Moreno-Koehler A, Sundberg A
Transpl Infect Dis
. 2023 May;
25(3):e14064.
PMID: 37154528
Background: Cytomegalovirus (CMV), a common post-transplant infection, is associated with increased healthcare resource utilization. In the Phase 3 SOLSTICE trial, maribavir was superior to investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, and...